

**Editorial**

- 173 C. Mannhalter; R. E. Scharf\*  
Impact-Faktor 2011 = 1,190





**Zu diesem Heft**

- 176 M. Moser; C. Bode  
*Are new antithrombotics the modern fountain of youth?*



**Innovative Antithrombotika**

- 177 E. Giannitsis; H. A. Katus  
*Antiplatelet therapy – ticagrelor*
- 186 H. Darius\*  
*Prasugrel*
- 191 K. A. L. Müller; T. Geisler; M. Gawaz  
*Elinogrel, an orally and intravenously available ADP-receptor antagonist – How does elinogrel affect a personalized antiplatelet therapy?*
- 195 T. Helbing; C. Bode; M. Moser\*  
*Rivaroxaban in der Prävention und Therapie thromboembolischer Erkrankungen*
- 203 S. Konstantinides; T. Münzel\*  
*Apixaban*
- 212 I. Ahrens; C. Bode  
*Oral anticoagulation with edoxaban – Focus on current phase III clinical development*
- 216 S. H. Hohnloser; H.-C. Diener  
*Dabigatran for stroke prevention in atrial fibrillation*
- 221 D. Duerschmied; C. Bode  
*Vorapaxar expands antiplatelet options – Which patients may benefit from thrombin receptor antagonist?*
- 228 T. Wurster; A. E. May  
*Atopaxar – A novel player in antiplatelet therapy?*



**News**

- 234 GTH-Mitteilungen
- 235 Mitteilungen des Berufsverbandes der Deutschen Hämostaseologen



**Verschiedenes**

- 237 Aktuelles Interview
- 239 Forum Thrombose
- 241 Aus Forschung und Industrie
- 242 Termine, Call for Papers

\*Article written in German.